What is known and objective: Therapeutic effects of anti-VEGF agents, corticosteroids and laser therapy have been previously examined for treating macular oedema secondary to branch and central retinal vein occlusion (BRVO and CRVO). However, anti-VEGF efficacy has not been previously compared to corticosteroid or laser therapy efficacy. We performed a meta-analysis to compare these treatments.
| WHAT IS KNOWN AND OBJECTIVE
Retinal vein occlusion (RVO) is thought to result from a thrombotic event or vessel wall pathology 1 and significantly reduces vision. 2 The prevalence of RVO is estimated at 5.20 cases per 1000 people 3 , and macular oedema secondary to RVO is the second most common retinal vascular disease after diabetic retinopathy. 3 Branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO) are the two major types of RVO and are named based on the location of the venous occlusion. 4 Serious consequences of RVO and its increasing prevalence make effective, widely applicable treatments necessary. For the past several decades, laser photocoagulation has been the primary RVO treatment. 5, 6 Moreover, intravitreal corticosteroid agents (eg triamcinolone and dexamethasone) have anti-inflammatory, antiangiogenic and anti-oedematous properties and have also been therapeutic options. 7 The recent introduction of vascular endothelial growth factor (VEGF) inhibitors 8 offers another effective option for treating RVO. Intravitreal anti-VEGF agents (eg ranibizumab, bevacizumab and aflibercept) have become a useful treatment because they significantly improve visual and anatomical outcomes in patients with macular oedema secondary to BRVO and CRVO. [9] [10] [11] Unfortunately, the different treatment strategies have not been directly compared. Therefore, a systematic review of randomized clinical trials (RCTs) is needed to compare the efficacies of anti-VEGF agents and non-anti-VEGF treatment strategies (eg intravitreal corticosteroids and laser therapy) for treating macular oedema secondary to RVO.
Previous meta-analyses of clinical trials that examined treating RVO with anti-VEGF agents have mainly focused on one anti-VEGF agent. 12, 13 However, given that the three most common anti-VEGF agents (ranibizumab, bevacizumab and aflibercept) all have the same therapeutic mechanism, data from studies with each of these agents can be combined into one group to expand the sample size. One such meta-analysis did not separate eyes with BRVO and CRVO when comparing different treatment strategies. 13 The current systematic review and meta-analysis were performed to overcome the shortcomings of these prior studies and to include data from the most recent RCTs.
Additionally, our analyses focus on comparing the efficacies of anti-VEGF and non-anti-VEGF treatment strategies for treating macular oedema secondary to BRVO and CRVO. We hope that our findings will aid treating ophthalmologists in choosing the best treatment options for their patients with RVO.
| METHODS

| Literature search
Literature searches were performed on articles published between corticosteroids (triamcinolone and dexamethasone) and laser photocoagulation. Language or study design restrictions were not used.
When titles and/or abstracts fit our search terms, abstracts were reviewed to exclude irrelevant studies (eg case reports, reviews or experimental treatments). We then carefully read all remaining articles to determine whether they contained data that were applicable to our study.
| Article inclusion/exclusion criteria
Articles were chosen for inclusion in our analyses using the fol- 
| Data extraction and quality assessment
The following information on study characteristics and clinical treatments was collected from all included studies: publication metrics (name of first author, year of publication, location of study and The status of each of the above items was listed as "yes" to indicate a low risk of bias, "no" to indicate a high risk of bias or "unclear" to indicate an unknown risk of bias. Chi-square tests were used to quantify statistical heterogeneity between studies. If no heterogeneity (P>.1 or I<50%) was observed, the fixed effect model was used to analyse data. If heterogeneity was observed, the random effect model was used. Forest plots were created to summarize weighted estimates, and funnel plots were created to display publication biases.
| Statistical analyses
| RESULTS
| Results of the literature search
The selection process of studies included in this meta-analysis is illustrated in Figure 1 
| Quality and characteristics of included studies
Eleven studies with a total of 1045 patients with macular oedema secondary to BRVO or CRVO were included in this meta-analysis. Basic study characteristics are summarized in Table 1 . Briefly, follow-up duration varied from 1 to 12 months and subject age and gender distribution did not significantly vary between anti-VEGF agent groups and non-anti-VEGF treatment groups. Additionally, the Jadad score was used to assess methodological quality and a bias risk assessment revealed that selection and performance biases were the most prevalent biases among studies (Figure 2 ).
| Visual acuity
The BCVA was the most important functional measure of treatment Figure 3D ). However, this difference between treatment groups was not statistically significant at 1 month (WMD: 0.14; 95% CI: −0.04 to 0.31; P=.13; Figure 3A) . Further, no heterogeneity was identified at any Figure 4B ).
P=.13;
| Central retinal thickness
The CRT represents anatomical changes in the fovea after treat- Figure 5C ) without Figure 6A ). 
| Efficacy of retinal vein occlusion treatments over time
| Treatment-induced intraocular pressure changes
Elevated IOP is a common adverse effect associated with the intravitreal anti-VEGF agent and corticosteroid use for treating retinal disease. 
| DISCUSSION
Laser photocoagulation has traditionally been the standard RVO treatment 5, 6 and has been widely used for several decades, in spite of its limits. Intravitreal corticosteroids (triamcinolone or Multiple studies have demonstrated the beneficial effects of intravitreal anti-VEGF injections and intravitreal corticosteroid/laser therapy on macular oedema associated with BRVO or CRVO ( Table 1) .
As a result, both treatment strategies have become popular and are increasingly being used to treat this condition. Unfortunately, the initial begin to decrease at 3 months, with BCVA being significantly worse at 6 months than at 3 months. The therapeutic effect of corticosteroid/laser therapy was even shorter, with the BCVA decline beginning at 1 month. These results suggest that the eye develops a resistance to corticosteroids and anti-VEGF agents and that BCVA improvement resulting from these drug treatments will not persist over the long term (defined here as ≥6 months). As a result of the short-lived treatment benefits, some studies compared combination treatments to monotherapies in eyes with macular oedema secondary to RVO.
Azad et al. 34, 35 showed that eyes with BRVO treated with laser and an anti-VEGF agent (ranibizumab or bevacizumab) had better 6-month outcomes than those treated with grid laser alone. In contrast, Cekic et al. 36 found similar treatment benefits of intravitreal bevacizumab, triamcinolone and bevacizumab/triamcinolone combination therapy at 1 month in eyes with BRVO. However, only eyes in the bevacizumab monotherapy group had BCVA improvements that persisted for 6 months. Furthermore, Fan et al. 37 reported that treating macular and CRT improvements for at least 6 months. Based on all of this evidence and the findings of the current meta-analysis, we conclude that intravitreal anti-VEGF agents are more effective than corticosteroid and laser therapy for improving BCVA and decreasing CRT in patients with macular oedema secondary to RVO. However, it should be noted that this may not be the case in all patients because triamcinolone 37, 38 and grid laser photocoagulation 39 
| WHAT IS NEW AND CONCLUSION
This meta-analysis indicates that intravitreal anti-VEGF injection therapy is more effective for treating RVO-induced macular oedema than laser and corticosteroid therapies, particularly in eyes with BRVO.
Furthermore, intravitreal anti-VEGF therapy is associated with a lower incidence of elevated IOP than intravitreal corticosteroid/laser therapy. Therefore, our results suggest that anti-VEGF therapies are a better choice than corticosteroid or laser therapies for treating macular oedema secondary to RVO.
This study had several limitations. First, our data contained some biases, which may have influenced our results. Second, because of our study design, the timing of follow-up data collection was sporadic and inconsistent over the 12-month period examined. For example, the observed CRT reduction at 1 and 12 months could not be adequately compared between the two treatment groups and intergroup differences did not meet the criterion for statistical significance (defined as P<.05). If more 1-and 12-month data had been included, identified differences would have likely been significant. Third, none of the 11 included studies differentiated between ischaemic and non-ischaemic RVOs, which may have introduced a major bias. Further long-term, prospective studies are needed to examine and compare the safety and efficacy of RVO-associated macular oedema treatment strategies. Including data from future studies in subsequent meta-analyses will improve conclusion accuracy and robustness and provide better clinical guidance.
